Perry Baromedical Corporation announced that the company has received the CE (Conformité Européene) Mark approval for their Sigma Series of Hyperbaric Chambers. The Sigma 34 and Sigma 40 represent the most technologically advanced family of Hyperbaric Therapy Systems available. The CE indicates that the product complies with the appropriate quality and safety standards and is another reflection of Perry’s commitment to providing their customers with the best equipment possible.
“We are pleased to be able to offer this valuable technology to physicians in the European Union for treating chronic non-healing wounds. This a huge step forward in providing our customers around the world and their patients with the best clinical outcomes in the market today for wound healing, “ said Wayne McCullough, President and COO of Perry Baromedical Corporation. For more information visit http://www.perrybaromedical.com
Hyperbaric Oxygen Therapy Has Become a Standard Medical Treatment
Currently, there are 13 approved conditions that Hyperbaric Oxygen Therapy can benefit, including chronic non-healing wounds, carbon monoxide poisoning and decompression sickness. The World Health Organization (WHO) estimates that approximately 10% of the estimated 180 million people worldwide who suffer from diabetes will be afflicted with chronic non-healing wounds. By administering pure oxygen in a pressurized chamber the body absorbs 10-15 times more oxygen then if delivered at sea level, promoting the body’s natural healing mechanisms. HBOT is a non-invasive, cost effective and safe treatment modality which has been proven successful in decreasing patient cost and increasing the patients quality if life.
